BioInvent International
BioInvent: Interview with CEO Martin Welschof and CMO Andres McAllister about ESMO and BI-1808 (Redeye)
2024-09-11 13:30
Redeye interviews CEO Martin Welschof, and CMO Andres McAllister, about the progress with BT-001 (oncolytic virus) and BI-1910 presented at ESMO. We also discuss the recent BI-1808 data in cutaneous t-cell lymphoma (CTCL).
info@redeye.se (Redeye.se)
Redeye AB - Redeye.se